The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
作者： C Buske , E Hoster , M Dreyling , H Eimermacher , H Wandt
DOI: 10.1038/LEU.2008.261
关键词: Lymphoma 、 Cyclophosphamide 、 Prednisone 、 Internal medicine 、 Vincristine 、 Rituximab 、 CHOP 、 Lymphoplasmacytic Lymphoma 、 Gastroenterology 、 Chemotherapy 、 Medicine 、 Surgery
摘要: Lymphoplasmacytic lymphoma (LPL) is an indolent with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab standard chemotherapy improves treatment outcome in LPL and subgroup patients fulfilling criteria Waldenstroem's macroglobulinemia (WM). A total 69 previously untreated were enrolled into trial; 64 evaluable for outcome. In all, 48 fulfilled WM. Patients randomly assigned R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine prednisone, n=34) or CHOP (n=30). resulted significantly higher overall response (OR) rate (94 vs 67%, P=0.0085) WM (91 60%, P=0.0188). With a median observation time 42 months, induced longer failure (TTF) 63 months 22 arm (P=0.0033) (P=0.0241). There was no major difference treatment-associated toxicity between both groups. These data indicate that front-line
nature.com
sci-hub.se 参考文章(31)
Bruce D. Cheson, Sandra J. Horning, Bertr Coiffier, Margaret A. Shipp, Richard I. Fisher, Joseph M. Connors, T. Andrew Lister, Julie Vose, Antonio Grillo-López, Anton Hagenbeek, Fernando Cabanillas, Donald Klippensten, Wolfgang Hiddemann, Ronald Castellino, Nancy L. Harris, James O. Armitage, William Carter, Richard Hoppe, George P. Canellos, Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas Journal of Clinical Oncology. ,vol. 17, pp. 1244- 1244 ,(1999) , 10.1200/JCO.1999.17.4.1244
Howard Ozer, Peter H. Wiernik, Francis Giles, Craig Tendler, Recombinant interferon‐α therapy in patients with follicular lymphoma Cancer. ,vol. 82, pp. 1821- 1830 ,(1998) , 10.1002/(SICI)1097-0142(19980515)82:10<1821::AID-CNCR3>3.0.CO;2-Q
Meletios Athanasios Dimopoulos, Athanasios Anagnostopoulos, Marie-Christine Kyrtsonis, Konstantinos Zervas, Constantinos Tsatalas, Garyfallia Kokkinis, Panagiotis Repoussis, Argyris Symeonidis, Souzana Delimpasi, Eirini Katodritou, Elina Vervessou, Evridiki Michali, Anastasia Pouli, Dimitra Gika, Amalia Vassou, Evangelos Terpos, Nikolaos Anagnostopoulos, Theophanis Economopoulos, Gerasimos Pangalis, Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide Journal of Clinical Oncology. ,vol. 25, pp. 3344- 3349 ,(2007) , 10.1200/JCO.2007.10.9926
Madhav V. Dhodapkar, Joth L. Jacobson, Morie A. Gertz, Saul E. Rivkin, G. David Roodman, Joseph M. Tuscano, Muhammad Shurafa, Robert A. Kyle, John J. Crowley, Bart Barlogie, Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. ,vol. 98, pp. 41- 48 ,(2001) , 10.1182/BLOOD.V98.1.41
Meletios A. Dimopoulos, Robert A. Kyle, Athanasios Anagnostopoulos, Steven P. Treon, Diagnosis and Management of Waldenstrom's Macroglobulinemia Journal of Clinical Oncology. ,vol. 23, pp. 1564- 1577 ,(2005) , 10.1200/JCO.2005.03.144
J Tamburini, V Lévy, C Chaleteix, J P Fermand, A Delmer, L Stalniewicz, P Morel, F Dreyfus, M J Grange, B Christian, S Choquet, V Leblond, Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Leukemia. ,vol. 19, pp. 1831- 1834 ,(2005) , 10.1038/SJ.LEU.2403885
Steven P. Treon, Pierre Morel, Veronique Leblond, Jean-Paul Fermand, Report of the Third International Workshop on Waldenström's Macroglobulinemia Clinical Lymphoma, Myeloma & Leukemia. ,vol. 5, pp. 215- 216 ,(2005) , 10.3816/CLM.2005.N.001
Constantine S. Tam, Max Wolf, H. Miles Prince, E. Henry Januszewicz, David Westerman, Katherine I. Lin, Dennis Carney, John F. Seymour, Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma Cancer. ,vol. 106, pp. 2412- 2420 ,(2006) , 10.1002/CNCR.21882
Ramón García‐Sanz, Silvia Montoto, Agustín Torrequebrada, Alfonso García De Coca, José Petit, Anna Sureda, José Antonio Rodríguez‐García, Pilar Massó, Ana Pérez‐Aliaga, María Dolores Monteagudo, Isabel Navarro, Gemma Moreno, Carmen Toledo, Aránzazu Alonso, Carles Besses, Joan Besalduch, Isidro Jarque, Perla Salama, José Angel Hernández Rivas, Blanca Navarro, Joan Bladé, Jesus F San Miguel, None, Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases British Journal of Haematology. ,vol. 115, pp. 575- 582 ,(2001) , 10.1046/J.1365-2141.2001.03144.X
Véronique Leblond, Vincent Lévy, Frédéric Maloisel, Bruno Cazin, Jean-Paul Fermand, Jean-Luc Harousseau, Liliane Remenieras, Raphaël Porcher, Martine Gardembas, Gérald Marit, Eric Deconinck, Bernard Desablens, François Guilhot, Guilaine Philippe, Aspasia Stamatoullas, Odile Guibon, Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease Blood. ,vol. 98, pp. 2640- 2644 ,(2001) , 10.1182/BLOOD.V98.9.2640